Major Research Activities
Using large administrative health databases and clinical trials, Dr. Rej’s research has focused on the pharmacoepidemiology of late-life bipolar disorder. An area of emphasis has been on finding ways to prevent and treat the kidney adverse effects of the gold-standard bipolar treatment, lithium. This work has been published in more than 60 peer-reviewed publications and has been kindly supported by the Canadian Institutes of Health Research (CIHR), Ontario Mental Health Foundation, Kidney Foundation of Canada and other agencies. Dr. Rej recently received the Chercheur-Boursier Clinicien Junior Investigator Award from the Fonds de recherche du Québec – Santé (FRQS).
Since 2015, Dr. Rej has also developed a secondary focus: clinical trials of mind-body interventions – such as meditation, tai chi, and yoga – in the treatment of late-life mood disorders, with the JGH Geri-PARTy research group and the McGill Meditation and Mind-Body Medicine Research Clinic (MMMM-RC). These trials have tailored mind-body interventions to novel populations and have increasingly examined the positive effects of these interventions on inflammation, vascular burden, and functional neural networks.
Soham Rej’s Publications Indexed on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/?term=soham+rej
Rej S, Herrmann, N., Shulman, K., Harel, Z., Fischer, H., Fung, K., Gruneir, A.“Lithium Use, but not Valproate Use, is Associated with Chronic Kidney Disease in Older Adults with Mental Illness: A Population-Based Nested-Case Control Study”, In Press (IF 5.8) Jan 2017.
Rej, S., Shulman, K., Herrmann, N., Harel, Z., Fischer, H., Fung, K., Gruneir, A., “Prevalence and Clinical Correlates of Renal Disease Amongst Late-Life Lithium Users: A Population-Based Cross-Sectional Study”. Am J Geriatric Psychiatry (IF 4.3). 2014 Nov;22(11):1075-82. doi: 10.1016/j.jagp.2014.01.015. PMID: 24566239
Marshe, V., Macieukiewicz, M., Rej, S., Tiwari, AK, Kennedy, JL, Lenze, E., Blumberger, D., Karp, J., Reynolds, CF., Mulsant, BH, Muller, DJ, “Norepinephrine Transporter (SLC6A2) Polymorphism rs2242446 (T-182C) is Associated with Remission on Venlafaxine in Late-Life Depression”, Am J Psychiatry (IF 12.3), 2017 May 1;174(5):468-475. Epub 2017 Jan 10. PMID: 28068779
Thomas Z, Novak M, Torres-Platas SG, Gauthier M, Potes A, Fox R, Segal M, Looper KJ, Lipman M, Selchen S, Mucsi I, Herrmann N, Rej S, “Brief Mindfulness Meditation for Depression and Anxiety Symptoms in Patients Undergoing Dialysis: A Randomized Controlled Feasibility Trial”, Clin J Am Soc Nephrology (IF 4.7) In Press.
Dr. Rej and colleagues have an active pharmacoepidemiology program examining the effects of medications on physical, cognitive, and mental health outcomes in older adults with bipolar disorder. His group is also using clinical trials to examine the effectiveness and neurobiology of mind-body interventions in late-life mood disorders.